Loading company…
TRIANA Biomedicines develops a molecular glue discovery platform focused on regulating disease-related proteins.
Founded in 2019 and based in Massachusetts, US, TRIANA Biomedicines develops technology to identify molecules that alter the function or fate of target proteins. Its research focuses on inducing or enhancing degradation of cancer targets. In April 2022, it raised an undisclosed amount of seed funding from RA Capital Management and Atlas Venture as part of a larger USD 110 million Seed and Series A funding. As of 2022, Patrick Trojer was president and CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in